XenoPort Urges Stockholders to Vote "FOR ALL" XenoPort Director Nominees on the WHITE Proxy Card
June 06 2014 - 8:30AM
Business Wire
XenoPort, Inc. (Nasdaq:XNPT) today reminded stockholders to
vote at the Company’s upcoming Annual Meeting of Stockholders on
June 11, 2014.
Time is short and stockholders are encouraged to vote the
WHITE proxy card today. XenoPort urges stockholders not to
return any proxy card sent to them by Clinton Relational
Opportunity Master Fund, L.P. and its affiliates (Clinton).
Even if stockholders have already voted using the gold proxy card,
they have the right to change their vote simply by executing and
submitting the WHITE proxy card in support of XenoPort’s
director nominees. Only the last-dated proxy card will count.
Stockholders can vote by telephone or Internet according to the
instructions on the WHITE proxy card. Voting by
telephone or Internet is the best way to ensure that votes will be
counted.
Two independent proxy advisory firms, Institutional
Shareholder Services (ISS) and Egan-Jones Proxy Services
(Egan-Jones), have recommended that XenoPort stockholders vote on
the WHITE proxy card “FOR ALL” of XenoPort’s director nominees:
Ronald W. Barrett, Ph.D., Jeryl L.
Hilleman and Wendell Wierenga, Ph.D.
XenoPort also urges stockholders to vote "FOR" the
approval of the XenoPort, Inc. 2014 Equity Incentive
Plan, vote "FOR" the approval, on an advisory basis, of the
compensation of XenoPort's named executive officers, and vote
"FOR" the ratification of the selection by the audit
committee of the Board of Directors of Ernst & Young
LLP as XenoPort's independent registered public accounting
firm for the fiscal year ending December 31, 2014. In
addition, the XenoPort Board urges stockholders to vote
"FOR" Proposals 9 through 14 and "AGAINST" Clinton
Proposals 5 through 8.
If you have any questions, require
assistance with voting your WHITEproxy card or need
additional copies of the proxy materials, please contact:
MACKENZIE PARTNERS, INC.
105 Madison AvenueNew York, NY 10016
proxy@mackenziepartners.com
(212) 929-5500 (Call Collect)OrTOLL-FREE
(800) 322-2885
Important Additional Information and
Where to Find It
XenoPort, Inc., its directors and certain of its executive
officers may be deemed to be participants in the solicitation of
proxies from stockholders in connection with XenoPort's 2014 Annual
Meeting of Stockholders. XenoPort has filed with
the SEC and provided to its stockholders a definitive
proxy statement and a WHITE proxy card in
connection with such solicitation. XENOPORT STOCKHOLDERS ARE
STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT (INCLUDING ANY
AMENDMENTS AND SUPPLEMENTS) AND THE
ACCOMPANYING WHITE PROXY CARD, AND ANY OTHER
RELEVANT DOCUMENTS WHEN THEY BECOME AVAILABLE, BECAUSE THEY CONTAIN
IMPORTANT INFORMATION.
Information regarding the names of XenoPort's directors and
executive officers and their respective interests
in XenoPort by security holdings or otherwise is set
forth in XenoPort's definitive proxy statement for the 2014 Annual
Meeting of Stockholders, filed with the SEC on April
22, 2014, including Appendix B thereto.
The definitive proxy statement (and amendments or supplements
thereto) and the accompanying WHITE proxy card,
and any other relevant documents and other material filed
by XenoPort with the SEC, are or will be available
for no charge at the SEC's website at www.sec.gov and at
XenoPort's investor relations website
at http://investor.xenoport.com/index.cfm. Copies may also be
obtained free of charge by contacting XenoPort Investor
Relations by mail at 3410 Central Expressway, Santa
Clara, California 95051 or by telephone at (408) 616-7200.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on
developing and commercializing a portfolio of internally discovered
product candidates for the potential treatment of neurological
disorders. XenoPort is currently commercializing
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets
in the United States and developing its novel fumaric
acid ester product candidate, XP23829, as a potential treatment for
psoriasis and/or relapsing forms of multiple sclerosis. REGNITE®
(gabapentin enacarbil) Extended-Release Tablets is being marketed
in Japan by Astellas Pharma Inc. XenoPort's pipeline
of product candidates also includes a potential treatment for
patients with Parkinson's disease. To learn more
about XenoPort, please visit the Web site
at www.XenoPort.com.
HORIZANT, REGNITE and XENOPORT are registered
trademarks of XenoPort, Inc.
XNPT2G
XenoPort, Inc.Jackie Cossmon, 408-616-7220ir@XenoPort.com
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Apr 2024 to May 2024
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From May 2023 to May 2024